Banner background image Banner background image

DISCOVER MORE ABOUT LEQVIO®

Browse our gallery of educational
resources to get to know LEQVIO
even
better through video content and
downloadable infographics

Body background image

NOW FEATURING

Recap the LEQVIO
Clinical
Story On-the-Go

Take a moment for a refresh of the entire LEQVIO
clinical story with insights into efficacy, dosing,
safety, and more!

WATCH play

EXPLORE LEQVIO INFOGRAPHICS

1648100806 1_lxunae4a

EXPLORE OUR MOST
RECENT RESOURCES

Body background image

LEQVIO: A Bold Way Forward

1648101222 1_bfwncktg
Body background image

LEQVIO: From Discovery to Development

https://novartispharma.widen.net/s/rzvj2qdc2z/164659-leq-from-discovery-to-development-infographic-12.21

WHAT MAKES
LEQVIO DIFFERENT

Explore the resources to dive even further into specific parts of the LEQVIO story and to see what makes LEQVIO different

EXPLORE CLINICAL EFFICACY RESOURCES arrow
Body background image

Explore the MOA

https://novartispharma.widen.net/s/tqtgjrgnkj/explore-the-moa-164678
Body background image

Dive Into siRNA Technology

https://novartispharma.widen.net/s/vjmwgb5xjd/dive-into-sirna-technology-164671

MECHANISM OF
ACTION

Take a look and become familiar with the LEQVIO mechanism of action

ACCESS MECHANISM OF ACTION RESOURCES arrow
Body background image

Lowering LDL-C With LEQVIO: Clinical Trial Data Overview

1648020553 1_xdv2fzbe
Body background image

ORION-10 Clinical Trial Design

https://novartispharma.widen.net/s/69zc82k8fj/orion-10-clinical-trial-design-158721

CLINICAL TRIAL DATA:
EFFICACY & SAFETY

See what LEQVIO can do for patients like yours

READ ABOUT LEQVIO CLINICAL DATA: EFFICACY & SAFETY arrow

WHAT MAKES
LEQVIO DIFFERENT

Explore the resources to dive even further into specific parts of the LEQVIO story and to see what makes LEQVIO different

EXPLORE CLINICAL EFFICACY RESOURCES arrow
  • Body background image

    LEQVIO: A Bold Way Forward

    1648101222 1_bfwncktg
  • Body background image

    LEQVIO: From Discovery to Development

    https://novartispharma.widen.net/s/rzvj2qdc2z/164659-leq-from-discovery-to-development-infographic-12.21

MECHANISM OF
ACTION

Take a look and become familiar with the LEQVIO mechanism of action

ACCESS MECHANISM OF ACTION RESOURCES arrow
  • Body background image

    Explore the MOA

    https://novartispharma.widen.net/s/tqtgjrgnkj/explore-the-moa-164678
  • Body background image

    Dive Into siRNA Technology

    https://novartispharma.widen.net/s/vjmwgb5xjd/dive-into-sirna-technology-164671

CLINICAL TRIAL DATA:
EFFICACY & SAFETY

See what LEQVIO can do for patients like yours

READ ABOUT LEQVIO CLINICAL DATA: EFFICACY & SAFETY arrow
  • Body background image

    Lowering LDL-C With LEQVIO: Clinical Trial Data Overview

    1648020553 1_xdv2fzbe
  • Body background image

    ORION-10 Clinical Trial Design

    https://novartispharma.widen.net/s/69zc82k8fj/orion-10-clinical-trial-design-158721

What Makes LEQVIO Different

Explore the resources below to dive even further into specific parts of the
LEQVIO story and to see what makes LEQVIO different

Body background image

LEQVIO: A Bold Way Forward

In this overview presentation, learn about what makes the LEQVIO clinical profile and dosing different

1648101222 1_bfwncktg
Body background image

Unmet Need in Patients With ASCVD

Dr Pam Taub and Dr Alan S. Brown provide insights on the state of cardiovascular disease and what makes LEQVIO such a...

1648020944 1_tgdxoad1
Body background image

Dosing and Administration: How to Give LEQVIO to Your Patients

Dr Alan S. Brown shares details on the LEQVIO dosing regimen—two doses a year after the first year—while highlighting...

1648020356 1_chjn6u8e
Body background image

LEQVIO: From Discovery to Development

LEQVIO is a small interfering RNA (siRNA) therapy that was studied in clinical trials to assess its efficacy and safety as a...

https://novartispharma.widen.net/s/rzvj2qdc2z/164659-leq-from-discovery-to-development-infographic-12.21
Body background image

How Is LEQVIO Dosing Different From PCSK9 mAbs?

Gain valuable insight from experts as they discuss how LEQVIO dosing differs from PCSK9 mAbs.

1663769565 1_fxjss2g7
Body background image

How Do You Explain the Value of LEQVIO to Your Patients?

Your patients will want to know the value of LEQVIO. Learn how to tell them in a way that will resonate.

1663777654 1_3agyet72

Mechanism of Action

Take a look and become familiar with the LEQVIO mechanism of action

Body background image

Explore the MOA

LEQVIO—harnessing the natural process of RNAi to lower LDL-C in certain patients with ASCVD on a maximally tolerated statin1

https://novartispharma.widen.net/s/tqtgjrgnkj/explore-the-moa-164678
Body background image

Dive Into siRNA Technology

LEQVIO—a small interfering RNA therapy that selectively targets the liver to regulate LDL-C levels1

https://novartispharma.widen.net/s/vjmwgb5xjd/dive-into-sirna-technology-164671
Body background image

Illustrated MOA

Watch the LEQVIO MOA come to life in this animated video

1648101100 1_maa5lj3s
Body background image

What's Different About the Way LEQVIO Lowers LDL Cholesterol Compared to PCSK9 mAbs?

LEQVIO is not another PCSK9 monoclonal antibody. It's something else...

1663777838 1_1yvyl6dt

Clinical Trial Data: Efficacy & Safety

See what LEQVIO can do for patients like yours

Body background image

LEQVIO: A Bold Way Forward

In this overview presentation, learn about what makes the LEQVIO clinical profile and dosing different

1648101222 1_bfwncktg
Body background image

Lowering LDL-C With LEQVIO: Clinical Trial Data Overview

Dr Alan S. Brown dives deeper into pivotal phase III clinical trial data for LEQVIO for patients with ASCVD, with a focus on...

1648020553 1_xdv2fzbe
Body background image

Recap the LEQVIO Clinical Story On-the-Go

Take a moment for a refresh of the entire LEQVIO clinical story with insights into efficacy, dosing, safety, and more!

1648100806 1_lxunae4a
Body background image

ORION-10 Clinical Trial Design

ORION-10 evaluated LDL-C reduction in certain patients with ASCVD1

https://novartispharma.widen.net/s/69zc82k8fj/orion-10-clinical-trial-design-158721
Body background image

Discover Clinical Efficacy & Safety

Take a deeper look at data supporting the efficacy and safety of LEQVIO.

https://novartispharma.widen.net/s/blcvkhrlp8/discover-clinical-efficacy--safety-159040
Body background image

How Do You Explain the Value of LEQVIO to Your Patients?

Your patients will want to know the value of LEQVIO. Learn how to tell them in a way that will resonate.

1663777654 1_3agyet72

Access & Acquisition

Gain valuable access and acquisition insight by exploring the videos below

Body background image

LEQVIO via Specialty Pharmacy

Gain insights into a third acquisition option for patients to acquire LEQVIO: a specialty pharmacy for in-office administration

1648018871 1_lngn2u2g
Body background image

LEQVIO via Buy-and-Bill With In-Office Administration

Find out more about acquiring HCP-administered products like LEQVIO through buy-and-bill, the primary method for...

1648019958 1_jkzyoboy
Body background image

LEQVIO via Referral to an Alternate Injection Center (AIC)

If buy-and-bill is not your method of choice for acquiring LEQVIO, get details on how you can refer patients to an AIC to handle...

1648019710 1_0y2f5bpm
Body background image

How Do You Get Your Patients Started on LEQVIO?

Watch our experts discuss the benefits of the 3 ways to acquire LEQVIO for patients.

1663778031 1_crd63beu

Expert Voices

Watch and learn what the experts have to say about LEQVIO

Body background image

Patients Who Could Benefit From LEQVIO

Dr Pam Taub and Dr Alan S. Brown describe a few types of patients from their clinics who are struggling to achieve the recommended...

1648020145 1_ze2rk93k
Body background image

How is LEQVIO Dosing Different From PCSK9 mAbs?

Gain valuable insight from experts as they discuss how LEQVIO dosing differs from PCSK9 mAbs.

1663769565 1_fxjss2g7
Body background image

What's Different About the Way LEQVIO Lowers LDL Cholesterol Compared to PCSK9 mAbs?

LEQVIO is not another PCSK9 monoclonal antibody. It's something else...

1663777838 1_1yvyl6dt
Body background image

How Do You Explain the Value of LEQVIO to Your Patients?

Your patients will want to know the value of LEQVIO. Learn how to tell them in a way that will resonate.

1663777654 1_3agyet72
Body background image

How Do You Identify Appropriate Patients with ASCVD for LEQVIO?

Follow along with our diverse panel of HCPs as they dive into the keys to identifying patients appropriate for LEQVIO.

1663777944 1_vkt6lth8
Body background image

How Do You Get Your Patients Started on LEQVIO?

Watch our experts discuss the benefits of the 3 ways to acquire LEQVIO for patients.

1663778031 1_crd63beu

HELPFUL LEQVIO RESOURCES

WHAT MAKES
LEQVIO DIFFERENT

6 RESOURCES arrow

MECHANISM OF
ACTION

4 RESOURCES arrow

CLINICAL TRIAL DATA:
EFFICACY & SAFETY

6 RESOURCES arrow

ACCESS &
ACQUISITION

4 RESOURCES arrow

EXPERT
VOICES

6 RESOURCES arrow
THERE'S MORE TO KNOW ABOUT LEQVIO

See how LEQVIO is there to support you and your patients

EXPLORE SUPPORT
AND ACCESS arrow
THERE'S MORE TO KNOW ABOUT LEQVIO

See how LEQVIO is there to support you and your patients

EXPLORE SUPPORT
AND ACCESS arrow

INDICATION AND IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION
AND INDICATION

COLLAPSE

EXPAND

INDICATION

LEQVIO (inclisiran) injection is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

Limitations of Use: The effect of LEQVIO on cardiovascular morbidity and mortality has not been determined.

IMPORTANT SAFETY INFORMATION

Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, urinary tract infection, diarrhea, bronchitis, pain in extremity and dyspnea.

Please click here for LEQVIO full Prescribing Information.

References: 1. LEQVIO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp. 2. Cubanski J, Damico A, Neuman T, Jacobson G. Sources of supplemental coverage among Medicare beneficiaries in 2016. KFF. November 28, 2018. Accessed November 5, 2021. https://www.kff.org/medicare/issue-brief/sources-of-supplemental-coverage-among-medicare-beneficiaries-in-2016/# 3. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430-1440. doi:10.1056/NEJMoa1615758 4. Data on file. Novartis Pharmaceuticals Corp; 2019. 5. Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625 6. Data on file. Novartis Pharmaceuticals Corp; 2020. 7. Ray KK, Wright RS, Kallend D, et al; ORION-10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387 8. European Medicines Agency. Annex I. Summary of Product Characteristics. Published December 9, 2020. Accessed August 4, 2022 . https://www.ema.europa.et1/en/documents/product-information/leqvio-epar-product- information_en.pdf 9. McClellan M, Brown N, Califf RM, Warner JJ. Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2019;139(9):e1-e11. doi:10.1161/CIR.0000000000000652 10. Jacobson TA, Cheeley MK, Jones PH, et al. The STatin Adverse Treatment Experience Survey: experience of patients reporting side effects of statin therapy. J Clin Lipidol. 2019;13(6):405-424. 11. Jones PH, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012;1(6):1-10. doi:10.1161/JAHA.112.001800 12. Fox KM, Tai M-H, Kostev K, Hatz M, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2018;107(5):380-388. doi:10.1007/s00392-017-1193-z 13. Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011–2012. J Clin Lipidol. 2016;10(5):1109-1118. doi:10.1016/j.jacl.2016.06.011

IMPORTANT SAFETY INFORMATION

Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, urinary tract infection, diarrhea, bronchitis, pain in extremity and dyspnea.

INDICATION

LEQVIO (inclisiran) injection is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

Limitations of Use: The effect of LEQVIO on cardiovascular morbidity and mortality has not been determined.

Please click here for LEQVIO full Prescribing Information.

References: 1. LEQVIO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp. 2. Cubanski J, Damico A, Neuman T, Jacobson G. Sources of supplemental coverage among Medicare beneficiaries in 2016. KFF. November 28, 2018. Accessed November 5, 2021. https://www.kff.org/medicare/issue-brief/sources-of-supplemental-coverage-among-medicare-beneficiaries-in-2016/# 3. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430-1440. doi:10.1056/NEJMoa1615758 4. Data on file. Novartis Pharmaceuticals Corp; 2019. 5. Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/
ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625 6. Data on file. Novartis Pharmaceuticals Corp; 2020. 7. Ray KK, Wright RS, Kallend D, et al; ORION-10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387 8. European Medicines Agency. Annex I. Summary of Product Characteristics. Published December 9, 2020. Accessed August 4, 2022. https://www.ema.europa.et1/en/documents/product-information/leqvio-epar-product-information_en.pdf 9. McClellan M, Brown N, Califf RM, Warner JJ. Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2019;139(9):e1-e11. doi:10.1161/CIR.0000000000000652 10. Jacobson TA, Cheeley MK, Jones PH, et al. The STatin Adverse Treatment Experience Survey: experience of patients reporting side effects of statin therapy. J Clin Lipidol. 2019;13(6):405-424. 11. Jones PH, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012;1(6):1-10. doi:10.1161/JAHA.112.001800 12. Fox KM, Tai M-H, Kostev K, Hatz M, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2018;107(5):380-388. doi:10.1007/s00392-017-1193-z 13. Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011–2012. J Clin Lipidol. 2016;10(5):1109-1118. doi:10.1016/j.jacl.2016.06.011